论文部分内容阅读
近25年来,一直认为胃复安只是一种止吐剂,仅作为麦角碱的铺助用约,本研究证实胃复安静脉注射是一种抗偏头痛的特效药,并配制出一种高效、头痛复发率低的口服制剂。 1986年,Raskin曾反复静脉注射麦角胺和胃复安治疗难治性头痛,经治病例89％的患者头痛症状在48小时内消失。首次试用盐酸麦角胺0.5mg,胃复安10mg解脉注射后有22％的患者好转。分析认为此作用与盐酸麦角胺和其代谢产物8 去氧盐酸麦角胺作用于血管和神经元有关,还发现胃复安具有拮抗5—HT_3受体的作用。5—HT_3受体与偏头痛的发病有关,其根据是与疼痛有关的部位有5—HT_3
For nearly 25 years, metoclopramide has been considered only as an antiemetic agent, which is only used as an excipient for ergot administration. This study demonstrates that metoclopramine is an anti-migraine specific agent and is formulated as a highly effective , Low rate of headache recurrence oral preparations. In 1986, Raskin had repeatedly received intravenous ergotamine and metoclopramide to treat refractory headache, and 89% of the treated patients had headache symptoms that disappeared within 48 hours. The first trial of ergotamine 0.5mg, metoclopramide 10mg Xiemai injection after 22% of patients improved. Analysis of this role and ergotamine hydrochloride and its metabolites 8 ergotamine oxyspiride on blood vessels and neurons, but also found that metoclop has antagonist 5-HT_3 receptor role. The 5-HT_3 receptor is associated with the onset of migraines based on the 5-HT_3